Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.
about
Taxane-containing regimens for metastatic breast cancerTaxane containing regimens for metastatic breast cancerTaxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review.Cancer drug related cardiotoxicity during breast cancer treatment.Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experienceA phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancerPhase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer.A Prospective Comparative Study of the Toxicity Profile of 5-Flurouracil, Adriamycin, Cyclophosphamide Regime VS Adriamycin, Paclitaxel Regime in Patients with Locally Advanced Breast CarcinomaCapecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane.Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer - results from the HER-OS patient registryFactors responsible for long-term survival in metastatic breast cancer.Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: a Pilot Phase I/II Feasibility StudyCardiotoxic effects of anthracycline-taxane combinations.Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.Targeting thyroid hormone receptor beta in triple-negative breast cancer.The Impacts of Inclusion in Clinical Trials on Outcomes among Patients with Metastatic Breast Cancer (MBC).Combination drug delivery approaches in metastatic breast cancerThe role of taxanes in the treatment of breast cancer.A network meta-analysis for toxicity of eight chemotherapy regimens in the treatment of metastatic/advanced breast cancerA systematic review of taxane-containing regimens for metastatic breast cancer.Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancerProgression-free survival as a surrogate endpoint in advanced breast cancerPhase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancerMulticentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer.Indication of metronomic chemotherapy for metastatic breast cancer: Clinical outcomes and responsive subtypesDrug resistance and the role of combination chemotherapy in improving patient outcomes.Attenuation effect of Abnormal Savda Munziq on liver and heart toxicity caused by chemotherapy in mice.Evolving options for the treatment of metastatic breast cancer: progression-free survival as an endpoint.Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer.New approaches in the management of advanced breast cancer - role of combination treatment with liposomal doxorubicin.Metronomic chemotherapy for metastatic breast cancer to prolong time to treatment failure to 12 months or more.Quality of life assessments in advanced breast cancer: should there be more consistency?Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.Taxane therapy for early stage breast cancer.Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group.Nanostructured Lipid Carrier Co-loaded with Doxorubicin and Docosahexaenoic Acid as a Theranostic Agent: Evaluation of Biodistribution and Antitumor Activity in Experimental Model.Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers.
P2860
Q24187214-7F150FE3-07B4-4365-927B-F70C2757A89AQ24246978-14185D91-5DAF-4A8A-8D0B-1DC36E750A13Q30251429-C96A90EE-1D8B-47A5-865C-698D3C670A0CQ30251498-5BFCE568-7998-44FC-9738-690E06F433DDQ33237182-7855E39F-539B-4D08-A0C2-CABA05593113Q33244593-C9C0EB63-B46C-4A37-98E4-9820F211292CQ33425130-23B4D669-3FD5-4A83-9E09-571EF45E422AQ33429967-DCD557DC-2233-46CE-9453-0A467ED3EC3FQ33631745-7FC2BFC0-D725-4596-AC0B-9C4B950BB691Q34503715-DD71E98C-1ADA-4506-B10B-3B3BE905704CQ34537146-E2CFB4C2-6F47-46C2-83AE-7F3646A87026Q35180995-5EEED2E8-944C-497C-BDC4-4E3C958EA7F6Q35194442-EB306EED-ECAA-40D1-9342-0FDF39267374Q35490056-E026D225-4E32-447F-8176-857432E9F660Q35564703-F2EBC8C1-DCB1-4DB0-BB76-DF3E74BF91A4Q35930745-C0247ECA-A271-48B7-9314-F31D882DADB4Q35955198-75547DA0-17DF-4C4E-B808-258771F5099AQ36163956-FED5765B-E8AE-40B6-8245-F644F1A751A0Q36181844-F6933B23-D30F-40C0-A07E-7550BAC0F4D7Q36211570-F5DF5DEC-EEB4-462E-A739-3511A13A58BFQ36309823-E26A9390-6F0F-45FC-A870-6E4CE1AC9BBFQ36552307-FCC6A495-B686-43D0-B4C8-FA49AEBB90E9Q36616449-2B4262E1-B264-44B1-A22C-20D340CFC21EQ36673766-3497ED91-E6C2-4F6C-A64F-DD9431C61B1EQ36953443-D13F4433-1004-4A32-AD10-D82A71076B8CQ36999509-9306F169-4415-4D94-AE74-C44ADBF92F69Q37001844-52AB281A-6E14-421D-B863-C0F70B451FA4Q37292020-0E852700-DEB5-4700-A8E0-BAF4F499EED2Q37344525-024892A6-19FD-4077-A8A8-580644B896C6Q37355919-E5BF653E-AEC4-411F-9246-DDBF16702B3BQ37641082-90817B2C-B399-4163-A2A6-D71D313F7315Q38016575-D71F9D62-DE5A-489B-8EEA-EA684CFDB78CQ38695528-8F1442D4-EB8D-4273-8AE9-C3D1ADE602E9Q43068334-FE22EF77-EA46-4E6E-BC04-E069200E2A44Q43267052-F01CC10A-E2D0-403A-971C-95F6F7DCD8D4Q43639604-B6447A3C-8549-4EE4-BCB0-276D2C296DC7Q46209091-ED71DA0D-60E7-4C9F-A86F-D01A8C391B28Q50847750-A87B654B-6B4A-46E6-B65A-253E716C9F36
P2860
Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Doxorubicin and paclitaxel ver ...... d phase III multicenter trial.
@en
type
label
Doxorubicin and paclitaxel ver ...... d phase III multicenter trial.
@en
prefLabel
Doxorubicin and paclitaxel ver ...... d phase III multicenter trial.
@en
P2093
P1476
Doxorubicin and paclitaxel ver ...... ed phase III multicenter trial
@en
P2093
A Płuzańska
Central & Eastern Europe and Israel Pacitaxel Breast Cancer Study Group
T Nagykalnai
P304
P356
10.1200/JCO.2001.19.6.1707
P407
P577
2001-03-01T00:00:00Z